logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12290531 B1

PDFFull Text
Date of Patent:
May. 06, 2025

Filed:

Apr. 19, 2024

Compositions targeting bcma and methods of use thereof

Applicant:

Takeda Pharmaceutical Company Limited, Osaka, JP;

Inventors:

Michael Curley, Cambridge, MA (US);

Ertan Eryilmaz, Cambridge, MA (US);

Shawn Jennings, Cambridge, MA (US);

LeeAnn Talarico, Cambridge, MA (US);

Taylor Hickman, Cambridge, MA (US);

Christina Sheau Fen Wong, Cambridge, MA (US);

Kathryn Fraser, Cambridge, MA (US);

Haiqing Wang, Cambridge, MA (US);

Alessandra Piersigilli, Cambridge, MA (US);

Assignee:

Takeda Pharmaceutical Company Limited, Osaka, JP;

Attorney:

Proskauer Rose LLP

Primary Examiner:

Meera Natarajan

Assistant Examiner:

Francesca Edgingtongiordano

Int. Cl.
CPC ...
A61K 35/17 (2014.12); A61K 39/00 (2005.12); A61K 47/20 (2005.12); A61K 47/26 (2005.12); A61K 47/42 (2016.12); A61P 35/02 (2005.12); C07K 16/28 (2005.12);
U.S. Cl.
CPC ...
A61K 35/17 (2012.12); A61K 39/4613 (2023.04); A61K 39/4631 (2023.04); A61K 39/464416 (2023.04); A61K 47/20 (2012.12); A61K 47/26 (2012.12); A61K 47/42 (2012.12); A61P 35/02 (2017.12); C07K 16/2878 (2012.12); A61K 2239/13 (2023.04); A61K 2239/21 (2023.04); A61K 2239/25 (2023.04); A61K 2239/48 (2023.04); C07K 2317/565 (2012.12);
Abstract

This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.

Find Patent Forward Citations

Curley, Michael. (2025). Compositions targeting bcma and methods of use thereof (U.S. Patent No. 12290531). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12290531

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…